PURPOSE - To evaluate the oncologic outcomes between adjuvant radiotherapy (ART) and salvage radiotherapy (SRT) in patients with locally advanced prostate cancer or with adverse pathologic factors including positive surgical margin and high Gleason score.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS - We searched the literature published from January 2000 until December 2014 at MEDLINE, PubMed, Web of Science, Embase, ProQuest, and Cochrane Library. To be specific, included were studies comparing ART and SRT settings if they followed up oncologic outcomes more than 5 years.
RESULTS - Overall, 3 retrospective, nonrandomized, observational studies, 1 matched control analysis, and 3 prospective randomized controlled studies met our inclusion criteria including a total of 2,380 patients (1,192 ART vs. 1,188 SRT). Higher favorable results were found in ART than in SRT was seen in the 5-year and 10-year biochemical recurrence (BCR)-free survival (risk ratio [RR], 0. 61 and 0. 70; 95% confidence interval [CI], 0. 54-0. 69 and 0. 63-0. 76). ART had a significantly higher 5-year progression-free survival rate than that in SRT (RR, 0. 64; 95% CI, 0. 51-0. 80), but this was not the same for the 10-year progression-free survival rate (RR, 0. 88; 95% CI, 0. 72-1. 08). There was no significant difference for the 5-year and 10-year overall survival rates between ART and SRT (RR, 0. 80 and 0. 94; 95% CI, 0. 59-1. 07 and 0. 80-1. 11).
CONCLUSIONS - ART showed favorable results in BCR-free survival during the 5-year follow-up period. However, the 10-year progression-free survival and overall survival did not show any difference between ART and SRT.
Korean journal of urology. 2015 Nov 09 [Epub]
Ja Yoon Ku, Chan Ho Lee, Hong Koo Ha
Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. , Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. , Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. ; Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.